Hvilken er prisen på Fresh Tracks Therapeutics, Inc. (FRTX)

Prisen på Fresh Tracks Therapeutics, Inc. (FRTX) er $0.94

Hva er markedsverdien på Fresh Tracks Therapeutics, Inc. (FRTX)

Markedsverdien på Fresh Tracks Therapeutics, Inc. (FRTX) er $2.73M

Fresh Tracks Therapeutics, Inc. (FRTX) Fortjeneste per Aksje

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

År	EPS	Endre
2026 (TTM)	$-1.40	45.83%
2023	$-0.96	-86.96%
2022	$-7.36	-66.76%
2021	$-22.14	-42.30%
2020	$-38.37	-90.06%
2019	$-386.21	64.76%
2018	$-234.41	-26.00%
2017	$-316.76	12.28%
2016	$-282.12	-11.05%
2015	$-317.17	-45.79%
2014	$-585.11	-48.36%
2013	$-1.13K	35.04%
2012	$-839.10	163.45%
2011	$-318.51	-80.01%
2010	$-1.59K	-16.62%
2009	$-1.91K	-34.48%
2008	$-2.92K	1.08%
2007	$-2.89K	24.38%
2006	$-2.32K	-25.69%
2005	$-3.12K	-5.25%
2004	$-3.29K	-14.06%
2003	$-3.83K	-12.52%
2002	$-4.38K	201.59%
2001	$-1.45K	6.63%
2000	$-1.36K	0.00%

År

EPS

Endre

2026 (TTM)

$-1.40

45.83%

2023

$-0.96

-86.96%

2022

$-7.36

-66.76%

2021

$-22.14

-42.30%

2020

$-38.37

-90.06%

2019

$-386.21

64.76%

2018

$-234.41

-26.00%

2017

$-316.76

12.28%

2016

$-282.12

-11.05%

2015

$-317.17

-45.79%

2014

$-585.11

-48.36%

2013

$-1.13K

35.04%

2012

$-839.10

163.45%

2011

$-318.51

-80.01%

2010

$-1.59K

-16.62%

2009

$-1.91K

-34.48%

2008

$-2.92K

1.08%

2007

$-2.89K

24.38%

2006

$-2.32K

-25.69%

2005

$-3.12K

-5.25%

2004

$-3.29K

-14.06%

2003

$-3.83K

-12.52%

2002

$-4.38K

201.59%

2001

$-1.45K

6.63%

2000

$-1.36K

0.00%

Selskap	EPS	EPS-forskjell	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-1,337.14%	US
Argenx SE ARGX.US	$27.74	-2,081.43%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-1,078.58%	BE

Selskap

EPS

EPS-forskjell

Land